Hexagon Nutrition IPO | Should You Apply?

India’s rising focus on health, nutrition and food fortification is supporting demand for specialised nutrition solutions.

Hexagon Nutrition operates in this space with products across micronutrient premixes, clinical nutrition and therapeutic nutrition.

Now, the company is coming to market with a ₹138.87 crore IPO, entirely through an Offer for Sale of 3.09 crore shares, at a price band of ₹42 to ₹45 per share.

But the key question remains: Can Hexagon Nutrition scale in the growing nutrition and food fortification market while sustaining margins?

Here are the key details investors should know:

Hexagon Nutrition operates in the nutrition and food fortification space. In simple terms, it helps make food and nutrition products healthier by adding essential vitamins and minerals.

Its key brands include Pentasure, Obesigo, Pediagold and Nutrone.

The company operates four manufacturing facilities across India and Uzbekistan and exports products to more than 75 countries. It is also among India's largest premix manufacturers and a major supplier of micronutrient powders for global nutrition programs.

The company serves 3 key customer groups: 

• Consumers (B2C): Hexagon sells branded nutrition products under names such as Pentasure, Obesigo and Pediagold. These products are used for adult nutrition, weight management, pediatric nutrition and clinical nutrition.
• FMCG & Food Companies (B2B2C): This is the company’s largest business segment. Hexagon supplies customized vitamin and mineral premixes to food and beverage companies for products such as health drinks, biscuits, dairy products, edible oils and fortified foods.
• Governments & Global Health Organizations: Hexagon supplies therapeutic nutrition products and micronutrient powders used to combat malnutrition, particularly among children and mothers.

Revenue mix: Premix formulations contribute the largest share at around 51%, followed by branded nutrition products at 30% and therapeutic nutrition products at 18%.

Hexagon Nutrition IPO is a 100% offer for sale (OFS) of up to 3.09 crore equity shares, aggregating to ₹138.87 crore.

So, basically all the money raised through the IPO will directly go in the pockets of existing promoters and promoter group shareholders, including Arun Purushottam Kalkar, Subhash Purushottam Kalkar, Aditva Kelkar and Neetu Subhash Kelkar, providing them a partial exit and liquidity opportunity.

Hexagon has seen a steady growth in its revenue and profits. The company’s total income has grown steadily from ₹281.65 crore in FY23 to ₹331.29 crore in FY25. For the nine months ended December 2025, total income stood at ₹275.57 crore, suggesting a healthy revenue run-rate.

Its profit after tax (PAT) increased from ₹5.82 crore in FY23 to ₹24.38 crore in FY25, and further to ₹27.03 crore in 9M FY26. This indicates better operating leverage and improved cost efficiency.

Hexagon Nutrition operates in the nutrition and wellness space, with products across clinical nutrition, wellness, and micronutrient premixes. Its listed peers include Zydus Wellness and Nestlé India, which operate in adjacent consumer health and nutrition categories.

At the upper price band, Hexagon Nutrition is valued at a P/E of 24.38x and a post-issue market cap of around ₹553 crore. In comparison, Zydus Wellness trades at a P/E of 46.22x with a market cap of about ₹15,992 crore, while Nestlé India trades at a P/E of 88.86x with a market cap of over ₹2.67 lakh crore. The industry average stands at 67.54x. 

On headline valuations, Hexagon appears to be available at a discount to its listed peers. However, the discount must be viewed in context. Zydus Wellness and Nestlé India are far larger, more established businesses with stronger brands, deeper distribution, and longer listed track records.

 

Despite its strengths, the business carries several important risks. 
 

• Raw Material Volatility: Hexagon relies on vitamins, minerals and specialty nutrition ingredients, many of which are imported. Fluctuations in input costs or supply disruptions can pressure margins. 
• Capacity Utilisation: The company's manufacturing facilities are operating below installed capacity across several product categories. Improving utilisation will be important for driving operating leverage and profitability. 
• Product Quality & Compliance Risk: It has previously faced a Salmonella contamination incident and a micronutrient formulation error, both of which resulted in product destruction, operational disruption, and financial losses. For a nutrition company, quality failures can damage both profitability and reputation 
• Export Dependence: More than 55% of revenue comes from international markets. Changes in global nutrition program funding, trade regulations, currency movements, or geopolitical disruptions could affect demand and profitability. 
• Competition: Hexagon competes with both domestic and global nutrition players in premixes, clinical nutrition and food fortification solutions, making continuous innovation and customer retention critical.

Hexagon Nutrition offers exposure to India’s growing nutrition, wellness and food fortification market.

Its margins are improving, and at a P/E of 24.38x, the IPO is priced below listed peers and the industry average.

However, it is a much smaller business, with risks around exports, raw materials, quality compliance and capacity utilisation. The IPO is also entirely an OFS, so the company will not receive any funds.

High-risk investors may consider it for the long term. Conservative investors may wait for post-listing performance.

What are the IPO dates for Hexagon Nutrition IPO?
Hexagon Nutrition IPO opens on June 5, 2026 and closes on June 9, 2026. The shares are proposed to be listed on NSE and BSE.

What is Hexagon Nutrition IPO GMP?
Check Hexagon Nutrition IPO GMP here. GMP is unofficial and volatile, so it should not guide investment decisions. 

What is the lot size for retail investors?
The minimum lot size is 333 shares, requiring an investment of ₹14,985 at the upper price band of ₹45.

Is Hexagon Nutrition IPO a fresh issue or an OFS?
The IPO is entirely an Offer for Sale of 3.09 crore shares, aggregating to ₹138.87 crore. The company will not receive any proceeds.

Should I invest in the Hexagon Nutrition IPO?
Investors may find it interesting due to its presence in nutrition, food fortification and exports. However, they should consider risks like customer concentration, quality control, raw material volatility and valuation before applying.